by Clinical Neuropsychologist | Friday, July 5, 2024 | Dementia
Abstract INTRODUCTION Microtubule (MT) stability is crucial for proper neuronal function. Understanding MT dysregulation is critical for connecting amyloid beta (Aβ) and tau-based degenerative events and early changes in presymptomatic Alzheimer’s disease (AD)....
by Clinical Neuropsychologist | Friday, July 5, 2024 | Dementia
Abstract INTRODUCTION Dementia risk scores constitute promising surrogate outcomes for lifestyle interventions targeting cognitive function. We investigated whether dementia risk, assessed using the LIfestyle for BRAin health (LIBRA) index, was reduced by the...
by Clinical Neuropsychologist | Friday, July 5, 2024 | Dementia
Abstract Sex and gender—biological and social constructs—significantly impact the prevalence of protective and risk factors, influencing the burden of Alzheimer’s disease (AD; amyloid beta and tau) and other pathologies (e.g., cerebrovascular disease) which...
by Clinical Neuropsychologist | Thursday, July 4, 2024 | Dementia
Abstract INTRODUCTION Although poor glycemic control is associated with dementia, it is unknown if variability in glycemic control, even in those with optimal glycosylated hemoglobin A1c (HbA1c) levels, increases dementia risk. METHODS Among 171,964 people with type 2...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Accurate testing for Alzheimer’s disease (AD) represents a crucial step for therapeutic advancement. Currently, tests are expensive and require invasive sampling or radiation exposure. METHODS We developed a nanoscale flow cytometry...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract The Dominantly Inherited Alzheimer Network (DIAN) initially was funded by the National Institute on Aging (NIA) in 2008 and thus was able to adopt and incorporate the protocols developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that had...
